SUSTAINABLE PATIENT EXPERIENCES

DASSAULT SYSTEMES

Sastry CHILUKURI
Co-CEO Medidata

Rajesh MALIK
Chief MedicalOfficer, G1 Therapeutics

DASSAULT SYSTEMES

SYNTHETIC CONTROL ARM®: MEDIDATA'S HISTORICAL TRIAL DATA AND EXPERIENCE IN REGULATORY SETTINGS IS A TRUE DIFFERENTIATOR

Celsion Corporation | MEDICENNA™ | PLUS™ THERAPEUTICS

4

Favorable regulatory outcomes

300+

Annual requests globally including: Big Pharma, Mid-Market, Biotech, Government

~20+

Indications, including GBM, Ovarian Cancer, ALL, NSCLC, SCLC, mHSPC, Breast Cancer, CNS

BIOPHARMA DEPLOYING SOLUTIONS END-TO-END

Lifecycle

Discovery & Research

Make better Go / No-Go decisions

Improve speed and success of trials

Clinical Development

Demonstrate value to regulators, payers, and patients

Commercialization

Launch to get the right treatment to the right patient

Disease Understanding Trial Design

Trial Operations Oversight & Rescue

Synthetic Control Arm® FDA, EMA, HTA



Longitudinal Patient Tracking in Real-Time

Commercial Data Solutions

EXAMPLE: CRS RISK STRATIFICATION MODEL FOR CAR-T





CAPITAL MARKETS DAY 2022

3S DASSAULT SYSTEMES